Larvol Delta - Development-of-BLX3030-a-Potent-and-Selective-Inhibitor-of-CDK9-for-the-Treatment-of-NMYC-Driven-NeuroEndocrine-Prostate-Cancers-NEPC

BLX-3030 - Biolexis Therap

https://www.aacr.org/wp-content/uploads/2023/09/MTCT2023_postersC_titles.pdf

Hariprasad Vankayalapati

Sep 16, 2023

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next